Inflammatory bowel diseases : Transformation of representations. A review
The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50-60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission - the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 95(2023), 12 vom: 28. Dez., Seite 1064-1074 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Maev, I V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.26442/00403660.2023.12.202507 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366495801 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366495801 | ||
| 003 | DE-627 | ||
| 005 | 20240108141333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2023.12.202507 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366495801 | ||
| 035 | |a (NLM)38158940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Maev, I V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammatory bowel diseases |b Transformation of representations. A review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50-60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission - the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a complications | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a extraintestinal manifestations | |
| 650 | 4 | |a inflammatory bowel diseases | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 700 | 1 | |a Bakulin, I G |e verfasserin |4 aut | |
| 700 | 1 | |a Skalinskaya, M I |e verfasserin |4 aut | |
| 700 | 1 | |a Skazyvaeva, E V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 95(2023), 12 vom: 28. Dez., Seite 1064-1074 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:12 |g day:28 |g month:12 |g pages:1064-1074 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/00403660.2023.12.202507 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 12 |b 28 |c 12 |h 1064-1074 | ||